Cassava Sciences

Inactive

SAVA (NCM)

Filana Therapeutics, Inc. is a clinical-stage biotechnology company focused on neurodegenerative diseases. Its lead candidate is simufilam, a small-molecule drug that has completed a Phase 2 trial. The company is developing SavaDx, a blood-based biomarker diagnostic for detecting Alzheimer’s disease. Formerly Cassava Sciences, Inc., it renamed to Filana Therapeutics in March 2026. It was incorporated in 1998 and is based in Austin, Texas.